Plain-English translation of NCT03180619 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hepatitis B research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial studied tenofovir alafenamide (), a medication used to treat chronic hepatitis B infection. Researchers tested whether this medication was safe and worked well in patients who had kidney or liver problems and were already taking other hepatitis B treatments. The goal was to see if the medication could help these patients while being gentler on their kidneys and liver than some older options.
Some people with hepatitis B who also have kidney or liver disease may have trouble tolerating older antiviral medications. This trial was designed to find out whether this newer treatment option could work just as well while causing fewer problems for people with these complications.
Participants who qualified switched from their current hepatitis B medication to the new treatment and took one tablet by mouth once daily for 96 weeks (nearly 2 years). During this time, they attended regular visits where doctors monitored their liver and kidney function, checked that their hepatitis B virus remained suppressed, and watched for any side effects or safety concerns.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States
Canada